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Basosquamous carcinoma of the skin is a relatively rare 
cutaneous neoplasm that has significant metastatic potential 
and a metastatic rate greater than that of basal cell and 
squamous cell carcinoma. We describe the use of lymphatic 
mapping and sentinel lymph node biopsy in a 63-year-old 
man after identification of basosquamous carcinoma. Sen-
tinel lymph node biopsy, which is a standard tool to detect 
regional lymphatic metastasis in cutaneous melanoma, has 
been rarely employed to detect lymphatic metastasis of 
basosquamous carcinoma. The approach was successful in 
detecting a regional lymphatic metastasis of two nodal basins 
with minor morbidity. Sentinel lymph node biopsy may be 
useful for certain high-risk lesions of basosquamous car-
cinoma. (Ann Dermatol 23(S1) S123∼S126, 2011)
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INTRODUCTION
Lymphatic mapping and sentinel lymph node biopsy 
(SLNB) is able to detect occult nodal metastasis with low 
morbidity rates in patients with cutaneous malignant 
melanoma
1. SLNB provides a minimally invasive way of 
assessing the metastatic status of draining the nodal basin. 
The use of SLNB in high-risk cutaneous squamous cell 
carcinoma (SCC) is at an early stage; only several case 
reports and case series have been published. Much work 
remains to define which patients with SCC have a high 
enough risk of nodal metastasis to warrant SLN exa-
mination
2.
Basosquamous carcinoma (BSC) is an entity that has been 
classified under basal cell carcinoma (BCC) for a long 
time. Clinically, however, the lesions are more akin to 
SCC
3. Several studies have revealed the striking metastatic 
potential of BSC, prompting increasing interest in its 
pathophysiology
4,5. BSCs have been associated with a 
high overall rate of metastases, which is much higher than 
BCC and even higher than ordinary SCC types
3. Unfor-
tunately, the rarity and disputed histopathology of this 
lesion have historically made categorization difficult and 
have contributed to a lack of awareness of its pathology 
and behavior. As surgeons play an integral role in the 
treatment of skin cancer, it is important that they be 
well-versed in the recognition of the risks and prognosis 
associated with BSC, to ensure proper management of this 
important entity
6. We herein report our experience of 
SLNB for a large primary BSC to highlight the prognostic 
importance of SLNB to detect lymphatic metastatic in this 
aggressive variant of skin cancer.I Jankovic, et al
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Fig. 2. Histopathological examination of the primary tumor. (A) Conventional basaloid tumor islands were admixed with more atypical
tumor cells demonstrating higher grade cytologic atypia with squamous differentiation (H&E stain, ×200). (B) A high power view 
revealing BCC cells with squamous differentiation (H&E stain, ×400).
Fig. 1. Photograph of the lesion. 
Fig. 3. SLN of the left axilla with metastatic BSC (CK AE1/AE3,
×10).
CASE REPORT
A 63-year-old male presented with a 6-month history of a 
rapidly growing, raised lesion in the middle of the back. 
The lesion measured 4 cm in maximal diameter (Fig. 1).
There was no palpable axillary and inguinofemoral lym-
phadenopathy.
The tumor was biopsied. In the lesion, conventional basa-
loid tumor islands were admixed with more atypical 
tumor islands demonstrating higher grade cytologic atypia, 
an increased nuclear to cytoplasmic ratio, prominent nu-
cleoli and variable pockets of keratinisation. A diagnosis 
of BSC was made (Fig. 2).
Pre-operative computed tomography of the chest and 
abdomen did not reveal evidence of distant metastasis or 
regional lymphadenopathy. We elected to perform a 
SLNB for regional pathologic staging of this high-risk 
lesion. Pre-operative lymphoscintigraphy documented the 
presence of discrete hot foci at both axillary sites. In the 
operating room, we injected 0.5 ml of isosulfan blue dye 
into the dermis around the primary tumor 10∼20 min 
prior to the operation. 
Wider excision margins are used when biopsy findings 
and lesion size indicate that a tumor is aggressive. In the 
present case, we excised the primary ulcerated lesion with 
a 2 cm radial skin margin and down to the muscle fascia, 
and then directly closed. Then, we first explored the left 
axilla through a short transverse incision over the hot spot 
in the mid axilla found by a handheld gamma probe. 
Deep to the clavipectoral fascia, we found and removed 
hot, blue SLN. After that, the right axilla was explored. We 
found and removed a discrete hot and blue stained node. Basosquamous Carcinoma Sentinel Lymph Node Biopsy
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Fig. 4. SLN of the right axilla with isolated tumor cells of SCC
(CK AE1/AE3, ×20).
The two nodes were sent for permanent pathology.
Permanent histologic evaluation demonstrated a BSC with 
negative margins on the primary skin specimen. Immuno-
histochemical staining with cytokeratins AE1 and AE3 
confirmed the presence of SCC metastases in SLN of the 
left axilla (Fig. 3) and isolated tumor cells in SLN of the 
right axilla (Fig. 4).
Complete lymphadenectomy of the left axilla was 
performed 1 week later. Five of 14 LNs were positive for 
metastatic BSC in the therapeutic LN dissection. The 
patient’s recovery was uncomplicated. Oncology consul-
tation led to the recommendation of close follow-up exa-
minations without adjuvant chemotherapy or radiation. At 
a follow-up 16 months later found that the wounds well- 
healed, with no evidence of local recurrence or identi-
fiable metastases.
DISCUSSION
The incidence of BSC is ill-defined. However, two of the 
larger studies reported an incidence of BSC of 1.5∼2.7% 
of all skin carcinomas
4,5. Some common characteristics 
have emerged when many patients with BSC are com-
pared. BSC is most commonly found in the head and neck 
region, and less common in the trunk and limbs. 
Additionally, there is a male predominance and a mean 
age distribution in the 7th decade of life
4,5.
Albeit relatively rare, it is the metastatic potential of this 
lesion that is most concerning. To date, studies of BSC 
have been hindered by small cohorts and debates over 
histology, but there is an overall trend toward greater 
metastases than with BCC, and possibly even SCC. In a 
cohort of 28 cases of BSC, five patients developed LN 
metastases, nine had recurrences and one had pulmonary 
metastases
4. In a study of 1,000 consecutive Mohs surgery 
cases, two of 228 cases (0.87%) of patients with SCC had 
pulmonary metastases, compared to two of 27 patients 
with BSC
5. In comparison, SCC has a reported incidence 
of regional nodal metastases of 2∼6%
7, BCC has a 
metastatic rate of less than 0.1%
8, while the reported BCS 
metastatic rate of 7.4% is much higher than BCC and even 
higher than ordinary SCC types
5.
Early treatment of subclinical nodal disease could lead to 
fewer deaths from SCC. The optimal surgical management 
of LNs remains controversial in clinically node negative 
(N0) patients. SLNB has recently started to be used in 
selected cases of high-risk cutaneous SCC. In patients with 
localized disease, metastasis to the regional LN basin is 
the strongest predictor of recurrence and survival; there-
fore, detecting subclinical metastatic disease is extremely 
important for staging certain skin cancers
2. Indeed, it may 
prove to be more sensitive in the detection of nodal 
micrometastatic disease than conventional nodal dissec-
tion
9. So, early diagnostic method like SLNB should be 
employed in BSC.
In the present case, we used a standard dual identity 
approach using both radiotracer and blue colloid dye, as 
is our current practice for melanoma.
The most appropriate treatment regimen for BSC remains 
to be established. Current standard of care is wide local 
excision, evaluation for metastasis to nodal basins and 
distant sites, and careful follow-up for recurrence and 
metastasis. The high rate of LN metastases on presentation 
of BSC should prompt consideration of SLNB in the 
absence of palpable lymphadenopathy
5.
Although uncommon among skin carcinomas, BSC com-
mands special attention for its diagnostic challenges and 
metastatic potential. It is vital that the treating physician 
appreciate the importance of early resection with free 
margins and a full workup for LN and distant metastases. 
He or she must also recognize the increased risk of 
metastases associated with lymphatic or perineural inva-
sion, male gender and large size; the latter also confers a 
potential risk of misdiagnosis. Familiarity with the peculiar 
histology and pathophysiology of these lesions will assist 
the dermatologist, surgeon and pathologist in the correct 
diagnosis, planning and treatment regimen, and give the 
patient the best chances for cure
6.
Future efforts should be directed at evaluating the utility of 
SLNB and to define patient populations most likely to 
benefit from this technique.
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